- Developing and applying artificial intelligence (AI) based image analysis for scoring PD-L1 immunohistochemistry in gastric cancer
This is a translational research trial and not open for patient recruitment.
Developing and applying artificial intelligence (AI) based image analysis for scoring PD-L1 immunohistochemistry in gastric cancer
Purpose of the Study
Advanced gastric cancer causes over 1000 deaths per annum in Australia. Immunotherapy using antibodies targeting programmed cell death 1 (PD1) or programmed cell death ligand 1 (PD-L1) has emerged as an important therapeutic opportunity in a range of cancers including gastric cancer. This study aims to use AI to develop an algorithm to enable computer based selection of which gastric cancers would be most suitable for immunotherapy treatment. After training an AI model on an initial training dataset, the study will then compare standard pathologist based testing of the expression of the protein PD-L1 against the predicted output from the trained AI model. If the AI based method is effective, it could enable a more systematic and cheaper method to identify cohorts of gastric cancer patients suitable for immunotherapy based on PD-L1 expression.
Professor Niall Tebbutt
2021 Gastric Cancer Grant
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.